Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) on November 15 and set a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback